|
Gleason score
| |
|
6
|
8 (20.0%)
|
|
7
|
12 (30.0%)
|
|
8–10
|
20 (50.0%)
|
|
T stage (AJCC 8th)
| |
|
T2
|
33 (82.5%)
|
|
T3
|
5 (12.5%)
|
|
T4
|
1 (2.5%)
|
|
aTx
|
1 (2.5%)
|
|
Risk group
| |
|
Low
|
2 (5.0%)
|
|
Intermediate
|
14 (35.0%)
|
|
High
|
23 (57.5%)
|
|
aUnknown
|
1 (2.5%)
|
|
Initial PSA
| |
|
< 10 ng/mL
|
16 (40.0%)
|
|
10–19.9 ng/mL
|
13 (32.5%)
|
|
≥ 20 ng/mL
|
11 (27.5%)
|
|
Parameter
|
Volume (cc)
|
|
CTV/median (range, cc)
|
92.85 (48.08–164.94)
|
|
≤ 100.00
|
68.44 (48.08–94.5) (52.5%)
|
|
> 100.00
|
121.37 (107.42–164.94) (47.5%)
|
|
Rectum/median (range, cc)
|
50.66 (34.59–75.29)
|
|
≤ 50.00
|
44.04 (34.59–49.89) (47.5%)
|
|
> 50.00
|
56.19 (50.41–75.29) (52.5%)
|
